MAP2K7 and neoplasm: Suppressing PDPK1 combined with MEK inhibitor (trametinib) treatment decreased cell proliferation in MEK inhibitor‐resistant cells, increased the CD8+ T cells in the TME, and suppressed tumor growth [259].